{{Short description|Pharmaceutical drug}} {{more citations needed|date=June 2019}} {{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 477858959 <!-- Clinical data --> | tradename = Protropin | Drugs.com = {{drugs.com|CONS|somatrem}} | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X --> | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> | legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> <!-- Identifiers --> | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 82030-87-3 | ATC_prefix = H01 | ATC_suffix = AC02 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB09098 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = CU8D464EDW | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D05884 | ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL = 1201620 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none <!-- Chemical data --> | chemical_formula = | C=995 | H=1537 | N=263 | O=301 | S=8 }}
'''Somatrem''', sold under the brand name '''Protropin''', is an analogue of growth hormone (GH).<ref name="pmid3300150">{{cite journal | vauthors = Flodh H | title = Present situation worldwide regarding the use and clinical experience of Somatonorm (somatrem) | journal = Acta Paediatrica Scandinavica. Supplement | volume = 331 | issue = | pages = 1–4 | date = 1987 | pmid = 3300150 | doi = 10.1111/j.1651-2227.1987.tb17089.x | s2cid = 20410776 }}</ref>
==Overview== Somatrem is a recombinant human growth hormone used for the treatment of short stature due to decreased or absent secretion of endogenous growth hormone.
Somatrem was first marketed under the brand name Protropin by Genentech in 1985.<ref>{{cite web|url=https://www.gene.com/media/press-releases/4235/1985-10-18/fda-approves-genentechs-drug-to-treat-ch|title=Genentech: Press Releases - Friday, Oct 18, 1985|website=www.gene.com}}</ref> It differs from endogenous growth hormone by the addition of an extra methionine at the N-terminus<ref>Growth hormone therapy#cite note-32</ref>{{Circular reference|date=May 2019}}.
Somatrem has largely been replaced by somatropin, marketed by several companies including by Genentech as the brand Nutropin.
==References== {{Reflist}}
==External links== * {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/somatrem | archive-url = https://web.archive.org/web/20190628225358/https://druginfo.nlm.nih.gov/drugportal/name/somatrem | url-status = dead | archive-date = June 28, 2019 | work = Drug Information Portal | title = Somatrem }}
{{GH/IGF-1 axis signaling modulators}} {{Pituitary and hypothalamic hormones and analogues}} {{Portal bar | Medicine}}
Category:Peptides Category:Growth hormones Category:Drugs developed by Hoffmann-La Roche Category:Drugs developed by Genentech
{{Systemic-hormonal-drug-stub}}